Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 3, 1998, Pages 203-209

  Washington, Carla B ^a   Duran, George E ^b   Man, Martha C ^a   Sikic, Branimir I ^a,b   Blaschke, Terrence F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bioavailability; Mdrl; Modulation; Nelfinavir; Ritonavir; Saquinavir

Indexed keywords

AZIDOPINE; CYTOCHROME P450; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; INDINAVIR; NELFINAVIR; PACLITAXEL; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VALSPODAR; VINBLASTINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032211902     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199811010-00001     Document Type: Article

References (38)

1. Balani SK, Arison BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995;23:266-70.
2. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase 1711 evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
3. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease. to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
4. + T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
5. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996;40:292-7.
6. Patick AK, Boritzki TJ, Bloom LA. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother 1997;41:2159-64.
7. Kitchen VS, Skinner C, Ariyoshi K. et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
8. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-7.
9. Pollard RB. Use of proteinase inhibitors in clinical practice. Pharmacotherapy 1994;14(6 Part 2):21S-29S.
10. Lea AP, Faulds D. Ritonavir, Drugs 1996;52:541-6;547-8.
11. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-6.
12. Jacobsen H, Haenggi M, Ott M, et al. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 1996;29:95-7.
13. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
14. Korneyeva M, Molla A, Kempf D, et al. Clinical and virological responses to ritonavir, an inhibitor of HIV protease [abstract Mo.B. 1137]. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
15. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
16. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
17. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
18. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-8.
19. Fisher G, Lum B, Sikic BI. Clinical studies with modulators of multidrug resistance. In Fisher G and Sikic B, eds. Drug resistance in clinical oncology and hematology. Philadelphia: WB Saunders, 1995:363-82.
20. Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992;43:95-102.
21. Fisher GA, Lum BL, Hausdorff J, Sikic, BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996;32A:1082-8.
22. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995;35:432-6.
23. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031-5.
24. Harker WG, MacKintosh FR, Sikic BI. Development and Characterization of a Human Sarcoma Cell Line, MES_SA, Sensitive to Multiple Drugs. Cancer Res 1983;43:4943-50.
25. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variant, the human sarcoma cell line MES-SA. Cancer Res 1985;45:4091-6.
26. Bruggemann EP, Germann UA, Gottesman MM, Pastan I. Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J Biol Chem 1989;264:15483-8 [published erratum appears in J Biol Chem 1990;265:4172].
27. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987;262:7884-8.
28. Jaffrezou JP, Chen G, Duran GE, et al. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim Biophys Acta 1995;1266:1-8.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
30. Denizot F, Lang R. Rapid colimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89: 271-7.
31. Richman DD. HIV therapeutics. Science 1996;272:1886-8.
32. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995;36: 259-67.
33. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
34. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993;268:14991-7.
35. + T cells: a role in cytotoxic effector function. J Clin Immunol 1992; 12:451-8.
36. Evans CH, Baker PD. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin. Cancer Res 1992;52:5893-9.
37. Gollapudi S, Gupta S. Human immunodeficiency virus 1-induced expression of p-glycoprotein. Biochem Biophys Res Commun 1990;171:1002-7.
38. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985;313:1493-7.